Further analysis of the survival rate of patients with RPS6KB2 amplification versus those without in the above-mentioned cancer subtypes revealed a significant decline in the survival rate for patients with RPS6KB2 amplification in bladder and endometrial cancers (Figure 5B and Supplementary Table S3). Here, RPS6KB2 is linked to cancer.